1. Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant
- Author
-
Maxime Jullien, Marianne Coste‐Burel, Beatrice Clemenceau, Valentin Letailleur, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Berthe‐Marie Imbert, Jocelyn Ollier, Audrey Grain, Cyrille Touzeau, Philippe Moreau, Marie C Béné, Henri Vié, and Patrice Chevallier
- Subjects
allogeneic ,cellular response ,COVID‐19 ,hematological ,humoral response ,SARS‐CoV‐2 mRNA ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract The impact of pre‐transplant anti‐severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo‐HSCT) and/or their donors is reported here, showing that the persistence of anti‐SARS‐CoV‐2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti‐SARS‐CoV‐2 spike glycoprotein CD3+ T‐cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti‐SARS‐CoV‐2 vaccination of both recipients and donors before Allo‐HSCT.
- Published
- 2022
- Full Text
- View/download PDF